<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03213249</url>
  </required_header>
  <id_info>
    <org_study_id>201704134</org_study_id>
    <nct_id>NCT03213249</nct_id>
  </id_info>
  <brief_title>Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy</brief_title>
  <official_title>Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Plastic Surgery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast implants, either cosmetic or reconstructive, are among the most common procedures
      performed by plastic surgeons. Bacterial infections or biofilms are implicated in the
      majority of breast implant complications including infection requiring explantation, capsular
      contracture (CC), and/or breast-implant associated anaplastic large cell lymphoma (BIA-ALCL).
      The research team, which has already extensively characterized bacterial pathogenesis in the
      urinary tract and designed non-antibiotic therapeutics to reduce the incidence of
      catheter-associated urinary tract infections (CAUTIs), and proposal will study
      bacteria-breast implant interactions and explore further the impact of the breast microbiome.
      The proposed research provides a greater understanding of which bacteria can colonize breast
      implants, their source, and how effective antibiotic pocket irrigation is at eliminating
      them, and begins to examine the mechanisms by which bacteria bind and colonize the implant
      surface. These insights will set the groundwork for developing new therapeutic agents that
      can disrupt the binding of certain bacteria to breast implants. Strategies that minimize
      problems bacteria can cause, while avoiding antibiotics, will reduce bacteria-related implant
      complications, limit antibiotic-related side effects, and reduce bacterial resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of tissue expander(s) removed due to infection</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The bulk of analyses will be to study bacterial biofilm formation on the explanted breast tissue, skin/scar, drain, acellular dermal matrix, tissue expander, and capsule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of tissue expander(s) removed due to patient preference</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of implantation</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration the drain was in</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of development of an infection or a wound</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of capsular contracture</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Breast Implant Infection</condition>
  <condition>Mammoplasty</condition>
  <arm_group>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram cefazolin intravenous before surgical incision
Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists
Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling
Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 gram cefazolin intravenous before surgical incision
Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists
Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling
Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intraoperative pocket irrigation with normal saline</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed</description>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <other_name>Ancef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral skin- or nipple-sparing mastectomies</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue expander</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breast implant</intervention_name>
    <description>Standard of care
Either breast implant or autologous flap</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous flap</intervention_name>
    <description>Standard of care
Either breast implant or autologous flap</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acellular dermal matrix sling</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Arm 1: Intraoperative pocket irrigation with NS</arm_group_label>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin</intervention_name>
    <description>Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed</description>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
    <other_name>Garamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacitracin</intervention_name>
    <description>Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed</description>
    <arm_group_label>Arm 2: Intraoperative pocket irrigation with NS + antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Between 18 and 75 years of age, inclusive

          -  Undergoing bilateral mastectomy reconstruction with tissue expanders (ipsilateral
             therapeutic/contralateral prophylactic) planned to be exchanged for breast implants

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document

        Exclusion Criteria:

          -  Male
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence M Myckatyn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terence M Myckatyn, M.D.</last_name>
    <phone>314-996-8800</phone>
    <email>myckatyn@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence M Myckatyn, M.D.</last_name>
      <phone>314-996-8800</phone>
      <email>myckatyn@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Terence M Myckatyn, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Hultgren, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marissa Tenenbaum, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajiv Parikh, M.D., MPHS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

